These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 16213598)

  • 1. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo.
    Benveniste O; Jacobson L; Farrugia ME; Clover L; Vincent A
    J Neuroimmunol; 2005 Dec; 170(1-2):41-8. PubMed ID: 16213598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG).
    Chauhan M; Punga T; Punga AR
    Neurosci Res; 2013; 77(1-2):102-9. PubMed ID: 23933211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
    Farrugia ME; Kennett RP; Hilton-Jones D; Newsom-Davis J; Vincent A
    Clin Neurophysiol; 2007 Feb; 118(2):269-77. PubMed ID: 17157556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis.
    Boneva N; Frenkian-Cuvelier M; Bidault J; Brenner T; Berrih-Aknin S
    J Neuroimmunol; 2006 Aug; 177(1-2):119-31. PubMed ID: 16857268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myopathy, muscle atrophy and tongue lipid composition in MuSK myasthenia gravis.
    Nikolić AV; Bačić GG; Daković MŽ; Lavrnić SĐ; Rakočević Stojanović VM; Basta IZ; Lavrnić DV
    Acta Neurol Belg; 2015 Sep; 115(3):361-5. PubMed ID: 25253293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
    Farrugia ME; Bonifati DM; Clover L; Cossins J; Beeson D; Vincent A
    J Neuroimmunol; 2007 Apr; 185(1-2):136-44. PubMed ID: 17335909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
    Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
    Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are MuSK antibodies the primary cause of myasthenic symptoms?
    Selcen D; Fukuda T; Shen XM; Engel AG
    Neurology; 2004 Jun; 62(11):1945-50. PubMed ID: 15184594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
    Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
    J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis.
    Zouvelou V; Rentzos M; Toulas P; Evdokimidis I
    J Neuroimaging; 2011 Jul; 21(3):303-5. PubMed ID: 20002967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR.
    Martignago S; Fanin M; Albertini E; Pegoraro E; Angelini C
    Neuropathol Appl Neurobiol; 2009 Feb; 35(1):103-10. PubMed ID: 19187062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurophysiological characteristics of MuSK antibody positive myasthenia gravis mice: focal denervation and hypersensitivity to acetylcholinesterase inhibitors.
    Chroni E; Punga AR
    J Neurol Sci; 2012 May; 316(1-2):150-7. PubMed ID: 22251934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
    Caress JB; Hunt CH; Batish SD
    Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
    Sanadze AG; Sidnev DV; Karganov MIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis.
    Mori S; Shigemoto K
    Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
    Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
    Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.